NANOTEC and GPO to upgrade drug innovation in Thailand
To support projected growth of pharma market in the region
The partnership will help upgrade the research capabilities of the two Thai agencies and promote national competitiveness, said Soontorn Vorakul, acting managing director for the GPO.
‘The focus of the research collaboration will be in the area of cosmeceutical and drug delivery using nanotechnology,’ he said.
Professor Sirirurg Songsivilai, executive director of NANOTEC, added that the opportunities for nanotechnology in pharmaceutical manufacturing and development are enormous.
‘It is clear that the international pharmaceutical industry has embraced nanotechnology research in their manufacturing. It is essential for the GPO and NANOTEC to join forces and share expertise if we are to keep pace with drug discovery,’ he said.
Thailand will be the eighth largest economy in the Asia Pacific region by 2016, according to the Economist Intelligence Unit (EIU). GDP growth is projected to increase to 7.1% in the same period.
The EIU also projects an annual growth rate of around 0.7% and the population to be the ninth largest in the Asia Pacific region in five years’ time. The elderly population is also rising; Thailand is expected to have the eighth highest proportion in the Asia Pacific region by 2016.
By 2016 it is estimated that Thailand will have the seventh largest pharmaceutical market in the Asia Pacific region.
You may also like
Research & Development
![Anton Paar launches new UNHT series for next-generation nanoindentation]()
Anton Paar launches new UNHT series for next-generation nanoindentation
Read moreAnton Paar introduces the new UNHT Series, a new generation of nanoindentation systems designed to deliver reliable results, faster workflows, and greater versatility across a wide range of materials
Trending Articles
You may also like
Research & Development
![Rethinking the route to first-in-human studies]()
Rethinking the route to first-in-human studies
For sponsors, development activities and fragmented clinical supply can slow the path from candidate selection to first-in-human (FIH) dosing. A more integrated approach can reduce avoidable complexity while preserving the flexibility needed for early clinical programmes
Media
![CPHI Pharma Awards 2026 recognise Touchlight, SeraNovo and Almac among fifteen category winners in Milan]()
CPHI Pharma Awards 2026 recognise Touchlight, SeraNovo and Almac among fifteen category winners in Milan
Touchlight's dbDNA platform took Innovation Catalyst, SeraNovo's NanoGlass oral formulation won Finished Formulation and Almac Clinical Services claimed Supply Chain Excellence — with BMS's Emma Charles named Woman of the Year
Research & Development
![Stablepharma doses first participant in Phase IIb trial of fridge-free tetanus-diphtheria vaccine]()
Stablepharma doses first participant in Phase IIb trial of fridge-free tetanus-diphtheria vaccine
The 160-person non-inferiority study is the final development step for the StablevaX-reformulated vaccine SPVX02, before commercialisation of a cold-chain-independent alternative to Tetadif
Media
![CPHI Milan's inaugural Sustainability Summit brings 300+ companies together to tackle pharma's sustainability challenges]()
CPHI Milan's inaugural Sustainability Summit brings 300+ companies together to tackle pharma's sustainability challenges
The two-day programme addresses practical barriers to sustainable procurement, manufacturing and packaging — with hackathon-style sessions and cross-industry collaboration designed to move beyond targets into measurable operational action
Manufacturing
![Making blister package integrity testing decisions that QA can use]()
Making blister package integrity testing decisions that QA can use
A blister package integrity testing strategy should give QA evidence that is relevant, repeatable, and practical to review. That means understanding the pack format, the likely leak risk, the sampling approach, and the records needed for routine decisions